WISCONSIN— Moderna asked the Food and Drug Administration Thursday to approve their pediatric COVID-19 vaccine for the youngest of American; researchers and doctors, including at those UW Health, celebrated the news.

“The results nationally that have been released by Moderna show that the safety profile has been excellent.”“The vaccine itself is a two-dose vaccine at this point, separated by 28 days,” said Dr. Bill Hartman, the principal investigator for UW-Health’s Moderna pediatric COVID-19 vaccine trial. “The results nationally that have been released by Moderna show that the safety profile has been excellent.”

UW Health played a role in Moderna's testing process, helping the potential pediatric vaccine to get to this point.

"[It's] very protective against severe disease, hospitalization and long-term effects from COVID,” Dr. Hartman added.

Watch the entire interview above.